重组骨形态发生蛋白-7在骨损伤疾病治疗中的研究进展

骨形态发生蛋白-7(BMP-7)是具有强诱骨活性的蛋白质因子,已通过基因工程技术在体外得到表达,较长时间以来不断被应用于骨损伤疾病的研究,得到了确切的治疗效果。通过载体将BMP-7基因转入真核细胞,与生物聚合载体复合后植入体内,能表达并分泌活性的BMP-7,诱导骨细胞的生成,促进骨组织的修复,成为一种新的有效的治疗手段。     

骨形态发生蛋白-7及抑制性Smads在糖尿病肾病发生发展中的表达变化

本文采用免疫组化、Western blot及荧光实时定量PCR方法,动态观察链脲佐菌素（streptozocin,STZ）诱导的大鼠糖尿病肾病（diabetic nephropathy,DN）发生早期肾脏骨形态发生蛋白-7（bone morphogenetic protein-7,BMP-7）、Smad6、Smad7蛋白及mRNA表达。结果显示,在正常及DN大鼠肾小管均有BMP-7、Smad6、Smad7蛋白表达,以胞浆表达为主。DN大鼠BMP-7、Smad6蛋白表达较正常大鼠明显增多（P〈0．05）,且BMP-7的mRNA表达呈先增加后降低的状态;而Smad7蛋白和mRNA的表达均呈先增加后降低的状态。转化生长因子-β1（transforming growth factor-β1,TGF-β1）及Ⅰ型胶原（collagen typeⅠ,COL-Ⅰ）mRNA在DN大鼠肾脏表达较正常大鼠明显增多（P〈0．05）,且随着糖尿病进展有逐渐增加的趋势。结果提示,作为TGF-β超家族信号分子的一员,BMP-7信号及抑制性Smad通路在DN肾纤维化发生早期可能起重要的反馈性抑制作用。     

骨形态发生蛋白在人类肿瘤组织中的表达

骨形态发生蛋白（Bone morphogenetic proteins,BMPs）是转录生长因子8（transforming growthfactors-β,TGFβ）家族成员之一。研究显示,BMPs在心、。肾、肺、骨骼、神经组织等胚胎发育中起着非常重要的作用,它可调控细胞的增殖、分化、凋亡及决定细胞的命运,并对不同组织其作用不同。有资料显示BMPs在某些消化系统肿瘤中的表达发生改变,提示BMPs可能在肿瘤发生中发挥作用,但它对呼吸系统的肿瘤和疾病是否也有作用,目前尚不清楚,故本实验拟研究BMPs在呼吸系统肿瘤及某些疾病中的表达情况,为进一步探讨它在肿瘤及某些疾病中的作用提供证据。     

骨形态发生蛋白-7的研究进展

骨形态发生蛋白是近来研究较多的一种生物因子,属于TGF—β超家族的一员。最初发现的作用是异位诱导成骨,并根据这一特点应用于临床一些难治性骨缺损疾病的治疗。其成员BMP—7作为一种细胞因子,在与体内其他因子作用的基础上,对其他多种组织的发育及功能均有重要作用。     

骨形态发生蛋白在神经系统中的表达和功能研究进展

近年来,骨形态发生蛋白（bone morphogenetic proteins,BMPs）在神经系统中的功能越来越受到人们的关注,现已发现,不同亚型的BMPs在神经系统中的不同区域呈持续性表达,一系列体外和体内动物实验证明BMPs不仅在神经系统发育过程中发挥重要作用,并且在成熟神经系统受到损伤时具有神经保护和神经再生功能,其确切机制有待通过实验进一步阐明。     

人骨形态发生蛋白7在中国仓鼠卵巢细胞中的表达研究

目的:构建重组人骨形态发生蛋白-7(rhBMP7)表达质粒,并研究其在中国仓鼠卵巢细胞中的表达。方法:将hBMP7重组表达质粒电转到中国仓鼠卵巢细胞(CHO)中,并用DOT-BLOT和ELISA方法分析检测rhBMP7在重组CHO细胞中的表达。结果:hBMP7 cDNA整合到CHO细胞基因组中并被转录。点杂交和ELISA检测证实rhBMP7在CHO细胞中得到表达。结论:hBMP7成功在CHO表达系统中得到表达。     

TGF—β在前列腺癌骨转移中的研究进展

进展期前列腺癌多会发生骨转移,导致患者骨质破坏甚至死亡。前列腺癌发生骨转移的机制目前尚未研究清楚。既往多认为是因为前列腺癌细胞表面携带者容易在骨环境中生长的表型。但是目前多认为是肿瘤细胞与骨骼微环境之间的相互作用导致的结果。它们之间是通过细胞因子来传递信息。在众多因子中,TGF-β对前列腺癌骨转移灶中的各种细胞都起着重要作用。研究表明在体外实验中TGF-β的作用极易受到细胞生长环境的影响,表现出不同的功能。这提示着TGF-β信号通路和其他信号通路之间存在非常强的交互作用。本文的重点在于对TGF-β在前列腺癌骨转移中的作用研究进展进行综述,阐述TGF-β对转移灶中不同细胞的作用．为今后肿瘤的治疗研究寻找一个好的方向。     

人骨形态发生蛋白7（hBMP7）在毕赤酵母中的分泌表达

依据酵母密码子使用偏好性,利用重叠延伸PCR(OE-PCR)介导的定点突变方法,对人骨形态发生蛋白-7(human Bone Morphogenetic Protein-7,hBMP7)成熟肽编码序列进行改造,将毕赤酵母低频使用的精氨酸密码子CGG或CGA突变为高频使用的同义密码子AGA,明显提高了hBMP7成熟肽在毕赤酵母中的表达量摇瓶培养表达量为25.45mg/L,是改造前序列的4.6倍;TricineSDS-PAGE及Western-blotting结果表明,rhBMP7成熟肽分子量为18kD,以单体形式存在,具有良好的免疫原性;利用梯度浓度G418筛选到一株高拷贝整合的转化子,该转化子摇瓶表达量为45.45mg/L,约为单拷贝转化子的2倍。表达上清经阳离子交换介质SPSepharoseR○FastFlow纯化后,目的蛋白纯度达到90%。纯化后的样品与I型胶原混合冻干后埋植于小鼠股部肌袋内,能异位诱导间充质细胞分化形成软骨细胞。     

骨形态发生蛋白9定向诱导多潜能干细胞成骨分化

为确认和评价骨形态发生蛋白9(bone morphogenetic protein 9, BMP9)定向诱导多潜能干细胞成骨分化的能力,以鼠间充质干细胞C3H10、小鼠胚胎成纤维细胞(mouse embryonic fibroblasts,MEFs)和骨髓基质细胞(bone marrow stromal cell, BMSC)三种多潜能干细胞为目标细胞,用重组腺病毒的方法将BMP9导入细胞,通过荧光素酶报告基因实验、碱性磷酸酶(alkaline phosphatase,ALP)定量测定、钙盐沉积实验、real time PCR、动物实验和组织化学染色等方法,观察BMP9对于多潜能干细胞成骨分化的定向诱导作用．结果提示,BMP9能诱导C3H10、MEFs和BMSC细胞ALP的表达,且具有剂量依赖性．BMP9在体外能够促进C3H10细胞和MEFs细胞的钙盐沉积．经BMP9刺激后,C3H10细胞成骨相关基因ALP、Runx2、骨桥素(osteopontin, OPN)和骨钙素(osteocalcin, OC)的mRNA水平均增加．荧光素酶报告基因实验证实,BMP9可以活化Smad和成骨关键基因Runx2．动物实验和组织化学染色检查显示,BMP9可以诱导C3H10细胞在裸鼠皮下异位成骨,因此,BMP9具有定向诱导多潜能干细胞成骨分化的能力．     

New intracellular components of bone morphogenetic protein/Smad signaling cascades

Bone morphogenetic proteins (BMPs) regulate many processes in the embryo, including cell type specification, patterning, apoptosis, and epithelial-mesenchymal interaction. They also act in soft and hard tissues in adult life. Their signals are transduced from the plasma membrane to the nucleus through a limited number of Smad proteins. The list of Smad-interacting proteins is however growing and it is clear that these partners determine the outcome of the signal. We summarize the present status in BMP/Smad signaling, with emphasis on recently identified Smad partners and how these proteins may cooperate in the regulation of the expression of BMP target genes.     

BMSCs与PLGA三维生物支架复合修复喉软骨缺损的研究

目的 探讨骨髓间充质干细胞（bone marrow mesenchymal stem cells,BMSCs）与聚乳酸/羟基乙酸共聚物（poly (lactide-co-glycolide),PLGA）三维生物支架在软骨源性形态发生蛋白1（cartilage-derived morphogenetic protein 1,CDMP1）和转化生长因子－β1（transforming growth factor-β1,TGF-β1）作用下向软骨细胞表型分化及体内修复喉软骨缺损的能力。方法 在体外高密度细胞悬液与PLGA共同构筑的三维立体培养体系下CDMP1和（或）TGF-β1联合诱导BMSCs向软骨细胞分化,观察诱导后细胞表型的表达;将培养体系移植入动物体内,从大体、组织学方面观察其对喉软骨缺损的修复效果。结果 诱导后的培养体系可表达特异性软骨基质Ⅱ型胶原和GAG;将培养体系移植入动物体内,可有效的修复喉软骨缺损。结论 BMSCs与PLGA三维生物支架在CDMP1和TGF-β1作用下所得组织工程化软骨可以有效的修复喉软骨缺损。     

Growth factor regulation of human growth plate chondrocyte proliferation in vitro

Linear growth occurs as the result of growth plate chondrocytes undergoing proliferative and hypertrophic phases. Paracrine feedback loops that regulate the entry of chondrocytes into the hypertrophic phase have been shown and similar pathways likely exist for the proliferative phase. Human long-bone growth plate chondrocytes were cultured in vitro. The proliferative effects of a variety of factors were determined by [3H]thymidine uptake and the gene expression profile of these cells was determined by DNA microarray analysis. Serum, insulin-like growth factor (IGF)-I and -II, transforming growth factor-beta (TGF-beta, fibroblast growth factor (FGF)-1, -2, and -18, and platelet-derived growth factor (PDGF)-BB were potent stimulators of proliferation. FGF-10, testosterone, and bone morphogenetic proteins (BMP)-2, -4, and -6 inhibited proliferation. Microarray analysis showed that the genes for multiple members of the IGF-I, TGF-beta, FGF, and BMP pathways were expressed, suggesting the presence of autocrine/paracrine pathways that regulate the proliferative phase of growth plate-mediated growth.     

TGF-beta superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud

Protein-rich fractions inhibitory for isolated ureteric bud (UB) growth were separated from a conditioned medium secreted by cells derived from the metanephric mesenchyme (MM). Elution profiles and immunoblotting indicated the presence of members of the transforming growth factor-beta (TGF-beta) superfamily. Treatment of cultured whole embryonic kidney with BMP2, BMP4, activin, or TGF-beta1 leads to statistically significant differences in the overall size of the kidney, the number of UB branches, the length and angle of the branches, as well as in the thickness of the UB stalks. Thus, the pattern of the ureteric tree is altered. LIF, however, appeared to have only minimal effect on growth and development of the whole embryonic kidney in organ culture. The factors all directly inhibited, in a concentration-dependent fashion, the growth and branching of the isolated UB, albeit to different extents. Antagonists of some of these factors reduced their inhibitory effect. Detailed examination of TGF-beta1-treated UBs revealed only a slight increase in the amount of apoptosis in tips by TUNEL staining, but diminished proliferation throughout by Ki67 staining. These data suggest an important direct modulatory role for BMP2, BMP4, LIF, TGF-beta1, and activin (as well as their antagonists) on growth and branching of the UB, possibly in shaping the growing UB by playing a role in determining the number of branches, as well as where and how the branches occur. In support of this notion, UBs cultured in the presence of fibroblast growth factor 7 (FGF7), which induces the formation of globular structures with little distinction between the stalk and ampullae [Mech. Dev. 109 (2001) 123], and TGF-beta superfamily members lead to the formation of UBs with clear stalks and ampullae. This indicates that positive (i.e., growth and branch promoting) and negative (i.e., growth and branch inhibiting) modulators of UB morphogenesis can cooperate in the formation of slender arborized UB structures similar to those observed in the intact developing kidney or in whole embryonic kidney organ culture. Finally, purification data also indicate the presence of an as yet unidentified soluble non-heparin-binding activity modulating UB growth and branching. The data suggest how contributions of positive and negative growth factors can together (perhaps as local bipolar morphogenetic gradients existing within the mesenchyme) modulate the vectoral arborization pattern of the UB and shape branches as they develop, thereby regulating both nephron number and tubule/duct caliber. We suggest that TGF-beta-like molecules and other non-heparin-binding inhibitory factors can, in the appropriate matrix context, facilitate "braking" of the branching program as the UB shifts from a rapid branching stage (governed by a feed-forward mechanism) to a stage where branching slows down (negative feedback) and eventually stops.     

Enhanced endogenous bone morphogenetic protein signaling protects against bleomycin induced pulmonary fibrosis

Background

Effective treatments for fibrotic diseases such as idiopathic pulmonary fibrosis are largely lacking. Transforming growth factor beta (TGFβ) plays a central role in the pathophysiology of fibrosis. We hypothesized that bone morphogenetic proteins (BMP), another family within the TGFβ superfamily of growth factors, modulate fibrogenesis driven by TGFβ. We therefore studied the role of endogenous BMP signaling in bleomycin induced lung fibrosis.

Methods

Lung fibrosis was induced in wild-type or noggin haploinsufficient (Nog^+/LacZ) mice by intratracheal instillation of bleomycin, or phosphate buffered saline as a control. Invasive pulmonary function tests were performed using the flexiVent® SCIREQ system. The mice were sacrificed and lung tissue was collected for analysis using histopathology, collagen quantification, immunohistochemistry and gene expression analysis.

Results

Nog^+/LacZ mice are a known model of increased BMP signaling and were partially protected from bleomycin-induced lung fibrosis with reduced Ashcroft score, reduced collagen content and preservation of pulmonary compliance. In bleomycin-induced lung fibrosis, TGFβ and BMP signaling followed an inverse course, with dynamic activation of TGFβ signaling and repression of BMP signaling activity.

Conclusions

Upon bleomycin exposure, active BMP signaling is decreased. Derepression of BMP signaling in Nog^+/LacZ mice protects against bleomycin-induced pulmonary fibrosis. Modulating the balance between BMP and TGFβ, in particular increasing endogenous BMP signals, may therefore be a therapeutic target in fibrotic lung disease.     

Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis

Cancer stem cells are a distinct cellular population that is believed to be responsible for tumor initiation and maintenance. Recent data suggest that solid tumors also contain another type of stem cells, the mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs), which contribute to the formation of tumor-associated stroma.The Hoechst 33342 efflux assay has proved useful to identify a rare cellular fraction, named Side Population (SP), enriched in cells with stem-like properties. Using this assay, we identified SP cells in a prostate cancer xenograft containing human prostate cancer cells and mouse stromal cells. The SP isolation, subculture and sequential sorting allowed the generation of single-cell-derived clones of murine origin that were recognized as MSC by their morphology, plastic adherence, proliferative potential, adipogenic and osteogenic differentiation ability and immunophenotype (CD45⁻, CD81⁺ and Sca-1⁺). We also demonstrated that SP clonal cells secrete transforming growth factor β1 (TGF-β1) and that their inhibition reduces proliferation and accelerates differentiation.These results reveal the existence of SP cells in the stroma of a cancer xenograft, and provide evidence supporting their MSC nature and the role of TGF-β1 in maintaining their proliferation and undifferentiated status. Our data also reveal the usefulness of the SP assay to identify and isolate MSC cells from carcinomas.     

BMP-7: Therapeutic target for ocular fibrotic disorders

Scarring of cornea, glaucoma, after-cataract and also proliferative vitreoretinopathy(PVR) related tractional retina detachment, age related macular degeneration and diabetic retinopathy etc., which are the major and seriously impair vision diseases in eyes, with various appearance and different therapy method, but maybe they have the similar pathogenesis—fibrosis, and all the above ocular diseases can be regarded as fibrotic disorders. Thus inhibition of the fibrotic process may provide a potentially novel therapeutic approach to the treatment of these ocular diseases mentioned above. Now numerous studies have proved that BMP-7 significantly reversed renal, hepatic, pulmonary fibrosis, including inhibition of Transforming growth factor-β (TGF-β) production, suppression of epithelial-to-mesenchymal transition (EMT), and repair of severely damaged epithelial cells. So it is reasonable to refer that BMP-7 may have the same preventive effect in these ocular fibrotic disorders. A potential clinical therapy can be developed by using the anti-fibrosis effect of BMP-7.